



# Supplementary Data

## Supplementary Figure 1. Estimation of la/mUC cases in Costa Rica in year 1



# Supplementary Data

## Supplementary Figure 2. Acquisition costs of medication in the first year of treatment per treated patient in the cost-of-care model (CRC ₪)



Costs were calculated by multiplying the monthly acquisition cost by the median treatment duration reported in the respective clinical trials. For avelumab maintenance: CT, 3.7 months; avelumab, 5.8 months. For EV + PEM: EV, 7.0 months; PEM, 8.5 months. For NIV + CT: NIV, 7.4 months; CT, 4.1 months.

**Ave**, avelumab; **BSC**, best supportive care; **CT**, platinum-based chemotherapy; **EV**, enfortumab vedotin; **NIV**, nivolumab; **PEM**, pembrolizumab.

# Supplementary Data

## Supplementary Table 1. Subsequent treatment

	CT → BSC <sup>2</sup>	CT → ave + BSC <sup>2</sup>	EV + PEM <sup>3</sup>	NIV + CT <sup>4</sup>
Patients receiving subsequent treatment, %	72.0	52.9	29.0	35.5

# Supplementary Data

## Supplementary Table 2. Estimated patient numbers by scenario

	Current scenario					Revised scenario				
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 1	Year 2	Year 3	Year 4	Year 5
<b>Total</b>	13	13	13	14	14	13	13	13	14	14
<b>Scenario 1: EV + PEM</b>										
<b>EV + PEM</b>	0	0	0	0	0	2	3	4	5	6
<b>NIV + CT</b>	0	0	0	0	0	1	1	1	1	1
<b>CT → ave + BSC</b>	13	13	13	14	14	10	9	8	8	7
<b>Scenario 2: NIV + CT</b>										
<b>EV + PEM</b>	0	0	0	0	0	1	1	1	1	1
<b>NIV + CT</b>	0	0	0	0	0	5	7	8	10	11
<b>CT → ave + BSC</b>	13	13	13	14	14	7	6	4	3	1
<b>Scenario 3: CT → ave + BSC</b>										
<b>EV + PEM</b>	0	0	0	0	0	1	1	1	1	1
<b>NIV + CT</b>	0	0	0	0	0	1	1	1	1	1
<b>CT → ave + BSC</b>	13	13	13	14	14	10	11	12	12	12

Patient estimates were derived using available epidemiological and market share evidence and were validated with clinical experts. Patient estimates for year 1 are shown in Supplementary Figure 1. For subsequent years, the base population was adjusted according to the population growth rate (1.4%).

The estimated cumulative patient population over 5 years was 67 patients.

**Ave**, avelumab; **BSC**, best supportive care; **CT**, platinum-based chemotherapy; **EV**, enfortumab vedotin; **NIV**, nivolumab; **PEM**, pembrolizumab.

# Supplementary Data

## Supplementary references

1. Incidence of Malignant Tumors – Different Characteristics. Year 2022, prepared by the Directorate of Health Surveillance through the Health Indicators Unit and the National Tumor Registry of the Ministry of Health of Costa Rica.
2. Powles T, et al. *J Clin Oncol*. 2023;41(19):3486-92.
3. Powles T, et al. *N Engl J Med*. 2024;390(10):875-88.
4. van der Heijden MS, et al. *N Engl J Med*. 2023;389(19):1778-89.